Physician profile
Jack Rubio
NPI 1346236205
$54,850.50
in general payments reported to CMS, 2019-2025
17 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,732 · 2021: $4,686 · 2022: $7,824 · 2023: $16K · 2024: $7,355 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $22K · Food and Beverage: $1,747 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $22,000.00 |
| Food and Beverage | $1,747.16 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $25,541.67 | 2022-2024 | Auryon Laser System 100-120 Vac |
| Amgen INC. | $22,141.54 | 2019-2022 | |
| Boston Scientific Corporation | $2,160.81 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,026.54 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $1,386.53 | 2019-2020 | |
| Becton, Dickinson and Company | $568.94 | 2022-2025 | Lutonix Drug Coated Balloon |
| Ardelyx, INC. | $252.40 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Siemens Medical Solutions USA, INC. | $171.77 | 2025 | Cios Alpha |
| Akebia Therapeutics INC | $161.57 | 2024-2025 | Vafseo |
| Vifor Pharma, INC. | $158.46 | 2021-2025 | Veltassa, Korsuva |
| Novo Nordisk INC | $123.78 | 2024-2025 | Ozempic |
| Medtronic, INC. | $53.13 | 2022-2023 | Venaseal |
| Otsuka America Pharmaceutical, INC. | $29.91 | 2024 | Rexulti |
| Cormedix INC. | $25.50 | 2025 | Defencath |
| Nevro Corp. | $17.51 | 2023 | Senza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16.26 | 2022 | |
| Fresenius USA Marketing, INC. | $14.18 | 2023 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Rubio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.